Back to articles

Blood Cancer Battle Lines Redrawn: BeOne Medicines Unveils Game-Changing Data at EHA 2025!

Mia Thompson•Jun 12, 2025
A dynamic, abstract image depicting intertwined strands of DNA reforming and strengthening, with a bright light emanating from the center, symbolizing medical breakthrough and hope against a dark, cellular background representing cancer.
  • Revolutionary Treatments: BeOne Medicines showcases potent new data for sonrotoclax and BGB-16673, targeting resistant B-cell malignancies.
  • BRUKINSA's Continued Dominance: New findings reinforce BRUKINSA's superior efficacy and long-term benefits in CLL.
  • Hope for the Toughest Cases: Breakthroughs offer promise for patients who have relapsed or developed resistance to existing therapies.

Milan, Italy – The historic city, host to the EHA 2025 Congress (June 12-15)1, 3, 5, becomes the stage for a seismic shift in the fight against B-cell malignancies. BeOne Medicines (NASDAQ: ONC; HKEX: 06160; SSE: 688235) is electrifying the hematology world, presenting a torrent of compelling data that promises to redefine treatment for devastating diseases like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)7.

At the forefront is BRUKINSA (zanubrutinib), the company's globally recognized BTK inhibitor, which continues to set unparalleled standards. New data from the SEQUOIA Phase 3 trial demonstrated that BRUKINSA, especially when combined with venetoclax, delivers profound and lasting responses, achieving a staggering 92% 24-month progression-free survival (PFS) rate in frontline CLL patients, even those with high-risk mutations7. For patients with the challenging del(17p) mutation, BRUKINSA monotherapy showed remarkable durability, with 72.2% remaining progression-free at five years.

But BeOne is not resting on its laurels. The company unleashed a formidable one-two punch with its next-generation therapies. Sonrotoclax, a potentially best-in-class BCL2 inhibitor, delivered stunning overall response rates (ORR) of 96% in relapsed/refractory (R/R) CLL and 79% in R/R MCL when combined with BRUKINSA7. Hot on its heels, BGB-16673, a first-in-class BTK protein degrader, demonstrated robust antitumor activity with ORRs of 85% in R/R CLL/SLL and 84% in Waldenström macroglobulinemia, specifically designed to dismantle resistance mechanisms7.

"The updated data presented at EHA underscore the potential of novel approaches... to overcome known mechanisms of resistance and expand treatment options for patients," affirmed Stephan Stilgenbauer, Professor of Medicine at Ulm University, highlighting the critical need these advancements address.

These findings are not just numbers; they represent lifelines. BeOne's strategic assault on B-cell malignancies, built on innovative science, is paving the way for Phase 3 studies and future regulatory submissions for sonrotoclax and BGB-16673. With a global team of over 11,000, BeOne Medicines is forging a new era of hope, committed to radically improving access to transformative medicines for cancer patients worldwide. Learn more at www.BeOne.com and follow them on X, LinkedIn, and WeChat.

Investors can tune into BeOne’s R&D Day on June 26 via their website: ir.BeOne.com, ir.BeOne.com.cn, or sse.BeOne.com.

References

  1. ehaweb.org
  2. ehaweb.org
  3. www.bopa.org.uk
  4. www.cml-foundation.org
  5. oncodaily.com
  6. ashpublications.org
  7. www.nasdaq.com
  8. ehaweb.org

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.